GWPH - GW Pharmaceuticals' Epidiolex Wins New FDA Approvals
GW Pharmaceuticals' (NASDAQ: GWPH) cannabidiol (CBD) drug Epidiolex has been granted Food and Drug Administration approval for a new indication. Additionally, its previous approval has been expanded to cover a wider age range of patients.
The company announced Monday morning that the FDA had approved the oral solution of Epidiolex as a treatment for seizures in patients age 1 and older suffering from tuberous sclerosis complex (TSC) -- a rare genetic disorder in which benign tumors can grow throughout the body; the disease can also cause epilepsy.
The FDA also expanded its approval of Epidiolex to treat seizures in patients afflicted with Lennox-Gastaut syndrome or Dravet syndrome, two rare forms of epilepsy. As with TSC, the drug can now be administered to patients with these conditions who are age 1 and older.